The COVAIL study was a Phase 2 clinical trial that evaluated the effects of omicron-based COVID-19 vaccines in providing an increased level of protection against COVID-19 infection in comparison to a prototype mRNA. This study enrolled 706 participants across 22 US sites including the GW VRU. The results adds to the evidence that matching COVID-19 vaccines to the currently circulating strains should provide better protection.
The effect of Omicron BA.1-based booster mRNA vaccination on the incidence of COVID-19
Latest News
Uganda has detected what appears to be a localized outbreak of Marburg virus disease, with two cases identified in a single family, according to a source familiar with the situation, although the Ugandan government had not yet publicly confirmed the outbreak at the time of publication. The…
The GW VRU is a site for a clinical trial to examine Pfizer's new C. diff vaccine.
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
